Biosimilars Market Size
Biosimilar drugs are extremely identical to permitted on-going biologic drugs. "Copied" or approved copies of reference biological products under patented products are biosimilars or following-on-biologics. A critical part of the overall production process is the production and evaluation of bio-referential biologics. In the conservation of feasibility and consistency between initial and biosimilar goods, the rules for biosimilars play an important role. They encompass similar medical characteristics in terms of effectiveness, security, and usefulness to initial biological products. The development and approval of biosimilars with recommended biologics is a vital feature of the overall enhancement process. Rules and regulations for biosimilars play a significant function in preserving the feasibility and stability between original biologics and biosimilars products. Several regulatory bodies like EMA and FDA keenly control the biosimilar's profitability and enlargement.
Market Highlights
U.S Biosimilars market is estimated to reach USD 109.82 Million by 2030 from USD 22.12 Million in 2019. The market is anticipated to grow at a CAGR of 15.7% during the forecast period, i.e., 2020-2030. A growing number of patients affected by such illnesses would result in an increased incidence of chronic diseases throughout the world, in particular in developed countries, due to the increased sedentary lifestyle and the increasing practice of fast food consumption. The prevalence rate would thus raise the demand and acceptance of biosimilar drugs, stimulating business growth in the developed countries as well as in some areas. Moreover, escalating demand for Biosimilars due to low costs is likely to propel the overall market growth. According to a survey, biosimilars are projected to act as an important factor in improving the community health problem by catering to the requirements of the customer. Increasing emphasis on Research & Development activities, patent termination, current product endorsements, the cost-effectiveness of biosimilars, and reduction in healthcare costs are expected to boost the overall growth of the Biosimilars market.
Source: Fatpos Global
U.S Biosimilars Market: Segments
The U.S market has been segmented based on product type, application, and location. It has been further segmented by countries into Northern, Eastern, western and southern regions.
By Product Type (in %), US Biosimilars Market, 2019
The Recombinant non-glycosylated proteins segment is anticipated to register XX% of the volume share.
On the basis of product type, the biosimilars market is segmented into Recombinant non-glycosylated proteins and Recombinant glycosylated proteins. Recombinant non-glycosylated proteins are further segmented into human growth hormone, granulocyte colony-stimulating factor, insulin, and interferon. The Recombinant non-glycosylated proteins market held a market share of XX% in the year 2019 and is expected to grow at the fastest pace during the forecast period due to technological developments in cell technology and high-throughput logical methods are likely to facilitate efficient manufacturing of recombinant non-glycosylated proteins leading to improved sales.
By Application type (in %), US Biosimilars Market, 2019
Oncology segment accounted for XX% of the nation’s volume in 2019 and is poised to grow at the highest CAGR during the forecasted period
On the basis of application, the biosimilars market is segmented into Chronic & Autoimmune Disorders, Blood Disorders, Oncology, and Growth Hormone. Improvements in chemotherapy and cancer treatment have assisted a lot of patients to subsist, but several patients undergo negative impacts of chemotherapy leading to chemotherapy-induced anemia. Additionally, a surge in the number of people experiencing blood disorders like neutropenia, anemia, and others will enhance the sales of biosimilars. The recent sanction of biosimilars for cancer treatment and the fat number of oncology products in the channel is a major driving factor.
By Manufacturer type (in %), US Biosimilars Market, 2019
In-house manufacturing segment to boost the growth
On the basis of the manufacturer, the biosimilars market is segmented into In-house Manufacturing, and Contract Research & Manufacturing. The In-house manufacturing segment of the biosimilar market assists the businesses to check and measure each phase of the manufacturing and trims down other costs involved. Moreover, the elasticity and competence of the work offered by in-house manufacturing help the functional and monetary abilities of the company.
The region segment can be further divided into four major types including Eastern US, Northern US, Western US, and the Southern US.
Source: Fatpos Global
U.S Biosimilars Market: Drivers and Restraints
Cost-Effectiveness to increase the demand for the market
With the lifestyle becoming more sedentary and a growing number of people affected by chronic diseases, there needs to be an emphasis on reducing healthcare costs. Biosimilars are likely to play a crucial role as they are cost-effective and will save a huge amount of money becoming easily affordable for the general public. Moreover, an increase in Research & development activities, patent expiration of biologics, and other factors are likely to drive the overall growth of the market.
Huge costs involved are expected to hinder the market demand
In the less-developed and emerging nations, enormous costs associated with the production of biosimilar drugs would likely hinder progress. In the lack of strict legislation, consumer commitment to a brand, doctors' inability to prescribe biosimilars, and others, the growth of the biosimilars market is further hindered by the lack of customers' loyalty.
U.S Biosimilars Market: Region
U.S to hold the largest market share during the forecast period
U.S accounted for the major share of XX% during 2019 and is estimated to dominate the biosimilars market. The American market is to be propelled due to the prevalence of key research & development centers. Moreover, US is the most developed and economically stable nation, and major players belonging to the state are supposed to boost the overall growth in the development of biosimilars. Asia-Pacific is anticipated to register a healthy growth rate during the forecast period due to the increasing geriatric population, ill-eating habits of the millennial, rising consumption of tobacco and alcohol. These factors are to fuel the overall market growth.
The region segment can be further divided into four major types including Eastern US, Northern US, Western US, and the Southern US.
Source: Fatpos Global
The US Biosimilars Market is further segmented by region into:
Eastern US Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Northern US Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Western US Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Southern US Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
US Biosimilars Market: Competitive landscape
Biosimilar key players leverage advantages in orphan biosimilars. As inexpensive care choices for patients in need of biologics, biosimilars are growing rapidly. As new treatments are highly prevalent, corporations have a heightened aim to direct progress in biosimilars. Having expanded the availability of low-cost biology, companies are making growing efforts to meet unfulfilled patient needs of rare diseases. For instance, the strategic alliance for marketing CT-P10 and CT-P6 in the US & Canada was founded by Teva drug companies Ltd. and Celltrion Healthcare in October 2016.
US Biosimilars Market: Impact of COVID-19
There are many experimental regimens worldwide to try to find suitable for Covid-19. Hydroxychloroquine is used in one category of therapies, while antiviral drugs used in treating HIV are included in a second method for the cure. The market for specialized antivirals and antimalarials has increased demand for both of these methods. The pharmaceutical companies must also be viewed as an indicator of the off-label for these drug groups. At present, neither of these techniques has been approved by the WHO or speculated on whether one is better than the other.
Key Players
- Pfizer
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Apotex/Apobiologix
- Coherus Biosciences
- Merck & Co.
- Biogen
- Amgen
- Teva Pharmaceutical Industries
- STADA Arzneimittel
- Other prominent players
The U.S Biosimilars Market Report also contains an analysis of:
- U.S Biosimilars Market by segment:
- By Product Type
- Recombinant Non-Glycosylated Proteins
- Human Growth Hormone
- Granulocyte Colony-Stimulating Factor
- Insulin
- Interferon
- Recombinant Glycosylated Proteins
- Erythropoietin
- Monoclonal Antibodies
- Follitropin
- Low Molecular Weight Heparin
- By Application
- Hematology
- Oncology
- Autoimmune Disease
- Growth Hormone Deficiency
- Diabetes
- By Manufacturer
- In-house Manufacturing
- Contract Manufacturing
- US Biosimilars Market Dynamics
- US Biosimilars Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
Frequently Asked Questions (FAQ):
This report provides a detailed global analysis of the biosimilars market, including segmentation by product type (such as recombinant non‑glycosylated proteins, recombinant glycosylated proteins, peptides), by indication (oncology, autoimmune, blood disorders, etc.), by manufacturing model (in‑house vs outsourced), regional breakdowns (North America, Europe, Asia‑Pacific, Latin America, Middle East & Africa), as well as market size, share, key drivers, restraints and future forecasts.
Key drivers include increasing expiration of biologic drug patents, growing demand for cost‑effective therapeutic alternatives to originator biologics, rising incidence of chronic and autoimmune diseases, expansion in emerging medical markets, and regulatory frameworks that support biosimilar approvals and market entry globally.
The report highlights challenges such as complex and expensive manufacturing processes, high regulatory and approval hurdles for biosimilars, concerns around interchangeability and patient acceptance, competition from originator biologics and novel therapies, and variability in reimbursement or market access across countries.
Regions covered include North America, Europe, Asia‑Pacific, Latin America and Middle East & Africa. While mature markets like North America and Europe lead in value and approvals, significant growth potential is identified in Asia‑Pacific and Latin America where biosimilar adoption is accelerating and healthcare access is expanding.
This report is valuable for biopharmaceutical companies developing biosimilars, generic drug manufacturers, biotechnology service providers, investors evaluating the biologics landscape, regulatory consultants, strategic planners and healthcare policy‑makers. It provides insights on market size, trends, segmentation, competitive landscape and regional dynamics—enabling informed decision‑making for product development, investment and expansion.
Select License Type
.png){kind=icon}
